Abstract
In the manufacturing process, during our attempts to get a suitable polymorph by reacting the aqueous solution of l-arginine with 3-[4-[2-(phenoxazin-10-yl) ethoxy]phenyl]-2-ethoxypropanoic acid (ragaglitazar) in different solvents, we have encountered various polymorphic modifications. These forms were characterized using differential scanning calorimetry (DSC), thermogravimetric analysis TGA, and powder X-ray diffraction (PXRD) techniques. The polymorphic forms of arginine salt of ragaglitazar (I) defined below is known to lower sugar level, lower total cholesterol (TC); increase high-density lipoprotein (HDL) and decrease low-density lipoprotein (LDL), which have a beneficial effect on type-II diabetes, coronary heart disease, and atherosclerosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
